Anavex Q3 net income $7.8M on comp reversal; advances FDA/EMA regulatory plans

ANAVEX LIFE SCIENCES CORP.

Q3 FY2026 net income $7.8M ($0.08/share) vs net loss $13.2M ($0.16/share) in Q3 FY2025.
Cash $118.3M at June 30, 2026 (vs $102.6M at Sept 30, 2025); funds ops into mid-late FY2028.
Reversal of $17.4M stock-based comp (G&A $7.5M, R&D $9.9M) from employee terminations, mainly former CEO.
Submitted all AD clinical data to FDA; FDA Phase 3 AD-005 design talks planned; EMA scientific advice received June 2026.
Rett Phase 3 RS-005 (~170 pts): FDA meeting requested on pediatric inclusion; Fragile X IND due Sept; 10-Q filings pending.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.